OSR Holdings Gains 180-Day Nasdaq Extension, Eyes $30M Upfront VXM01 Deal
OSR Holdings received a 180-calendar-day extension to regain compliance with Nasdaq’s $1.00 minimum bid requirement, extending the deadline to August 31, 2026. The company is pursuing a VXM01 licensing deal with $30M upfront consideration plus $815M in milestone payments and consolidating its medical device platform.
1. Nasdaq Extension Details
OSR Holdings has been granted a 180-calendar-day extension by Nasdaq to meet the $1.00 minimum bid price requirement, moving the compliance deadline to August 31, 2026. Trading of common stock will continue without interruption during this period, giving the company additional runway to restore its listing status.
2. VXM01 Licensing Initiative
The company’s subsidiary Vaximm AG is advancing a global licensing transaction for its lead immuno-oncology asset VXM01, structured to deliver $30 million in upfront consideration (split evenly between cash and digital assets) and up to $815 million in performance-based milestone payments.
3. Medical Device Platform Merger
OSR is consolidating RMC and Woori IO into a unified medical technology and distribution platform. This merged entity will drive commercialization of Woori IO’s non-invasive glucose monitoring technology and is advancing international partnership discussions to expand its market reach.